{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:55:06Z","timestamp":1794866106623,"version":"4.9.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jhep.2024.01.014","type":"journal-article","created":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T06:37:27Z","timestamp":1706337447000},"page":"694-701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":331,"title":["Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-577X","authenticated-orcid":false,"given":"Zobair M.","family":"Younossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Stepanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8156-1672","authenticated-orcid":false,"given":"Janus","family":"Ong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2017-3526","authenticated-orcid":false,"given":"Saleh","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jhep.2024.01.014_bib1","first-page":"560","article-title":"Non- alcoholic fatty liver: assessment of variability in the pathologic interpretations","volume":"11","author":"Younossi","year":"1998","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.jhep.2024.01.014_bib2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.jhep.2024.01.014_bib3","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000251","article-title":"The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019","volume":"7","author":"Paik","year":"2023","journal-title":"Hepatol Commun"},{"issue":"4","key":"10.1016\/j.jhep.2024.01.014_bib4","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhep.2024.01.014_bib5","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.jhep.2024.01.014_bib6","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep4.1599","article-title":"The growing burden of disability related to nonalcoholic fatty liver disease: data from the global burden of disease 2007-2017","volume":"4","author":"Paik","year":"2020","journal-title":"Hepatol Commun"},{"issue":"12","key":"10.1016\/j.jhep.2024.01.014_bib7","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1016\/j.cgh.2021.10.018","article-title":"The impact of NASH to liver transplantations with hepatocellular carcinoma in the United States","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.01.014_bib8","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2024.01.014_bib9","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.cgh.2021.11.004","article-title":"Global NASH Council. Clinical and patient-reported outcomes from patients with nonalcoholic fatty liver disease across the world: data from the global non-alcoholic steatohepatitis (NASH)\/non-alcoholic fatty liver disease (NAFLD) registry","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2024.01.014_bib10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jceh.2022.12.005","article-title":"The growing economic and clinical burden of nonalcoholic steatohepatitis (NASH) in the United States","volume":"13","author":"Younossi","year":"2023","journal-title":"J Clin Exp Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2024.01.014_bib11","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhep.2024.01.014_bib12","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1053\/j.gastro.2008.08.050","article-title":"Nonalcoholic Steatohepatitis Clinical Research Network. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis","volume":"135","author":"Patton","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2024.01.014_bib13","article-title":"Global burden of non-alcoholic fatty liver disease (NAFLD) and chronic liver disease (CLD) among adolescents and young adults","author":"Paik","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2024.01.014_bib14","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/HEP.0000000000000383","article-title":"Global and national prevalence of nonalcoholic fatty liver disease in adolescents: an analysis of the global burden of disease study 2019","volume":"78","author":"Hartmann","year":"2023","journal-title":"Hepatology"},{"issue":"S1","key":"10.1016\/j.jhep.2024.01.014_bib15","first-page":"644A","article-title":"Lack of liver disease awareness: important contributor to late state hepatocellular carcinoma","volume":"72","author":"Rai","year":"2020","journal-title":"Hepatology"},{"issue":"S1","key":"10.1016\/j.jhep.2024.01.014_bib16","first-page":"403A","article-title":"Poor liver disease awareness among adults with NAFLD in the United States","volume":"72","author":"Biswas","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.01.014_bib17","article-title":"NAFLD Nomenclature consensus group. A multi-society Delphi consensus statement on new fatty liver disease nomenclature","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.01.014_bib18","article-title":"On behalf of the Global NASH Council. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease","author":"Younossi","year":"2023","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2024.01.014_bib19","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3350\/cmh.2023.0277","article-title":"Critical appraisal of metabolic dysfunction-associated steatotic liver disease: implication of Janus-faced modernity","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"23","key":"10.1016\/j.jhep.2024.01.014_bib20","first-page":"4996","article-title":"Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD","volume":"S0168\u20138278","author":"Ratziu","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"23","key":"10.1016\/j.jhep.2024.01.014_bib21","first-page":"5080","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical","volume":"S0168\u20138278","author":"Hagstr\u00f6m","year":"2023","journal-title":"J Hepatol"},{"issue":"23","key":"10.1016\/j.jhep.2024.01.014_bib22","first-page":"5000","article-title":"Can we use old NAFLD data under the new MASLD definition?","volume":"S0168\u20138278","author":"Song","year":"2023","journal-title":"J Hepatol"},{"issue":"23","key":"10.1016\/j.jhep.2024.01.014_bib23","first-page":"5232","article-title":"MASLD screening and diagnostic algorithms are interchangeable from existing NAFLD literature","volume":"S0168\u20138278","author":"Arora","year":"2023","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.jhep.2024.01.014_bib24","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1111\/liv.15695","article-title":"Exploring the landscape of steatotic liver disease in the general US population","volume":"43","author":"Ciardullo","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2024.01.014_bib25","unstructured":"National Center for Health Statistics (NCHS). Plan and operation of the third\u00a0national health and nutrition examination survey 1988-94. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Center for Disease Control and Prevention n.d. http:\/\/www.cdc.gov\/nhcs\/data\/series\/sr_02\/sr02_113.pdf (accessed August 16, 2016)."},{"key":"10.1016\/j.jhep.2024.01.014_bib26","series-title":"Gallbladder ultrasonography procedure manual","year":"1988"},{"key":"10.1016\/j.jhep.2024.01.014_bib27","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/hep.32499","article-title":"Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?","volume":"76","author":"Younossi","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2024.01.014_bib28","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/apt.15580","article-title":"The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease","volume":"51","author":"Paik","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jhep.2024.01.014_bib29","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/apt.17308","article-title":"Vigorous physical activity provides protection against all-cause deaths among adults patients with nonalcoholic fatty liver disease (NAFLD)","volume":"57","author":"Henry","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2024.01.014_bib30","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.13131","article-title":"National trends in American heart association revised life\u2019s simple 7 metrics associated with risk of mortality among US adults","volume":"2","author":"Han","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhep.2024.01.014_bib31","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/liv.13992","article-title":"Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease","volume":"39","author":"Paik","year":"2019","journal-title":"Liver Int"},{"issue":"12","key":"10.1016\/j.jhep.2024.01.014_bib32","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1016\/j.cgh.2021.12.015","article-title":"Prevalence of high and moderate risk nonalcoholic fatty liver disease among adults in the United States, 1999-2016","volume":"20","author":"Golabi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2024.01.014_bib33","series-title":"A\u00a0Pract Guide","first-page":"292","volume":"iii","author":"Allison","year":"1995"},{"issue":"2","key":"10.1016\/j.jhep.2024.01.014_bib34","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1097\/HEP.0000000000000706","article-title":"From NAFLD to MASLD: Promise\u00a0and\u00a0pitfalls\u00a0of a new definition\u2020","volume":"79","author":"Cusi","year":"2024","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhep.2024.01.014_bib35","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","article-title":"Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease","volume":"161","author":"Kanwal","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jhep.2024.01.014_bib36","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"8","key":"10.1016\/j.jhep.2024.01.014_bib37","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/hep4.1534","article-title":"Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities","volume":"4","author":"Golabi","year":"2020","journal-title":"Hepatol Commun"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824000564?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824000564?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T03:22:50Z","timestamp":1713324170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824000564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S0168827824000564"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.01.014","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}